AR128999A1 - Proceso mejorado para la fabricación de osimertinib - Google Patents

Proceso mejorado para la fabricación de osimertinib

Info

Publication number
AR128999A1
AR128999A1 ARP230100846A ARP230100846A AR128999A1 AR 128999 A1 AR128999 A1 AR 128999A1 AR P230100846 A ARP230100846 A AR P230100846A AR P230100846 A ARP230100846 A AR P230100846A AR 128999 A1 AR128999 A1 AR 128999A1
Authority
AR
Argentina
Prior art keywords
osimertinib
manufacture
improved process
salt
compound
Prior art date
Application number
ARP230100846A
Other languages
English (en)
Spanish (es)
Inventor
Alexander Kieron Mullen
Alessandro Pozzoli
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR128999A1 publication Critical patent/AR128999A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Epidemiology (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
ARP230100846A 2022-04-07 2023-04-05 Proceso mejorado para la fabricación de osimertinib AR128999A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202263362622P 2022-04-07 2022-04-07

Publications (1)

Publication Number Publication Date
AR128999A1 true AR128999A1 (es) 2024-07-03

Family

ID=86142780

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP230100846A AR128999A1 (es) 2022-04-07 2023-04-05 Proceso mejorado para la fabricación de osimertinib

Country Status (14)

Country Link
US (1) US20250250255A1 (https=)
EP (1) EP4504718A1 (https=)
JP (1) JP2025511404A (https=)
KR (1) KR20250002363A (https=)
CN (1) CN119317624A (https=)
AR (1) AR128999A1 (https=)
AU (1) AU2023250220A1 (https=)
CA (1) CA3255378A1 (https=)
CO (1) CO2024015096A2 (https=)
IL (1) IL316018A (https=)
MX (1) MX2024012370A (https=)
TW (1) TW202404955A (https=)
WO (1) WO2023194531A1 (https=)
ZA (1) ZA202408113B (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120717920A (zh) * 2025-08-18 2025-09-30 爱斯特（成都）生物制药股份有限公司 一种微通道连续合成3-硝基-4-氟苯腈的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4119551A1 (en) 2011-07-27 2023-01-18 Astrazeneca AB 2-(2,4,5-substituted-anilino)pyrimidine compounds
CN106883216B (zh) * 2017-04-06 2020-03-13 张家港威胜生物医药有限公司 一种奥希替尼的制备方法
IN201741031902A (https=) * 2017-09-08 2019-03-15 Msn Laboratories Private Ltd
CN109134435B (zh) 2018-10-29 2023-01-03 湖南大学 一种奥希替尼azd9291的合成方法

Also Published As

Publication number Publication date
JP2025511404A (ja) 2025-04-15
CN119317624A (zh) 2025-01-14
ZA202408113B (en) 2025-07-30
KR20250002363A (ko) 2025-01-07
TW202404955A (zh) 2024-02-01
WO2023194531A1 (en) 2023-10-12
MX2024012370A (es) 2024-11-08
AU2023250220A1 (en) 2024-11-07
IL316018A (en) 2024-11-01
CO2024015096A2 (es) 2024-11-28
EP4504718A1 (en) 2025-02-12
CA3255378A1 (en) 2023-10-12
US20250250255A1 (en) 2025-08-07

Similar Documents

Publication Publication Date Title
AR063710A1 (es) Proceso para la preparacion de acido 6-(3-cloro-2-fluorbencil)-1-[(s)-1-hidroximetil-2-metilpropil]-7-metoxi-4-oxo-1, 4-dihidroquinolon-3-carboxilico como inhibidores de integrasa del hiv e intermediarios de sintesis del mismo y composiciones que lo comprenden.
CL2020000407A1 (es) Proceso para preparar compuesto inhibidor de bet. (solicitud divisional 201803702).
AR111960A1 (es) Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
MX368631B (es) Composicion para el tratamiento de material de resina con ataque quimico.
AR128999A1 (es) Proceso mejorado para la fabricación de osimertinib
BR112017024235A2 (pt) processo para produção de um agente quelante, mistura de compostos, solução aquosa, e, uso de uma mistura ou de uma solução aquosa.
PE20231308A1 (es) Proceso e intermedios para preparar un inhibidor de jak1
AR064422A1 (es) Proceso de obtencion del acido 1-(2-etil-butil)-ciclohexanocarboxilico
AR116423A1 (es) Un proceso de fabricación de compuestos heterocíclicos de 2-nitroimino
AR064658A1 (es) Proceso para preparar duloxetina y sus compuestos relacionados, asi como tambien intermediarios utiles en la misma
EA201892211A2 (ru) Способ получения азоксистробина
MX2020011267A (es) Metodo de produccion para 4,5-dihidroisoxazol 5,5-disustituido.
MA38444B1 (fr) Procédé de concentration de métaux des terres rares dans du phosphogypse
AR128353A1 (es) Síntesis de un inhibidor de kif18a
MA39205A1 (fr) Polymères contenant des amines primaires utiles en tant qu'inhibiteurs de tartre
AR088358A1 (es) Proceso de obtencion de acidos isoxazolil-metoxi-nicotinicos
MX2024010712A (es) Sal de cabozantinib con ácido l-(+)-tartárico y formas sólidas de esta
AR126196A1 (es) Proceso para preparar inhibidores de egfr
WO2020127208A8 (en) Pharmaceutical process and intermediates
SA518400034B1 (ar) تخليق أملاح أدامانتان من فلز انتقالي ومواد مركبة من الأكسيد، وأنظمة وطرق تتضمن الأملاح أو المواد المركبة التي بحجم النانو
AR057909A1 (es) Proceso para preparar montelukast y compuestos relacionados, que utiliza un compuesto intermediario derivado de un ester sulfonico.
MX2024008385A (es) Inhibidor de la corrosion.
PH12018500677A1 (en) Method for producing optically active 2- (2-fluorobiphenyl-4-yl) propanoic acid
AR094954A1 (es) Preparación de 1,3-(diarilo sustituido)-1,2,4-triazoles e intermediarios derivados de ellos
PH12019500227A1 (en) Method for preparing a,b-unsaturated aldehyde